Linklaters advises DNB Markets and Carnegie Investment Bank as financial advisors on Alvotec’s triple listing on Nasdaq Stockholm

We have advised DNB Markets and Carnegie Investment Bank as financial advisors in connection with Alvotec's triple listing on Nasdaq Stockholm. Alvotech is a biotech company which specializes in developing and manufacturing biosimilar medicine for patients worldwide. Alvotech recently announced its acquisition of XBrane’s R&D operations in Sweden, affirming its global leadership position in biosimilar development and production and establishing its footprint in the Swedish life science sector. Alvotech is already listed on Nasdaq Global Market (New York) and Nasdaq Iceland.

The team was led by partner Charlotte Levin, managing associate Nima Naderi and associate Rick Cuperus (Corporate, Stockholm) along with partner Mike Bienenfeld (Corporate, London).